Profile for European Patent Office Patent: 3397250

US Patent Family Members and Approved Drugs for European Patent Office Patent: 3397250

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	May 20, 2038	Corium	ADLARITY	donepezil hydrochloride
	Aug 11, 2038	Corium	ADLARITY	donepezil hydrochloride
	Sep 23, 2037	Corium	ADLARITY	donepezil hydrochloride

European Patent Office Patent EP3397250: Scope, Claims, and Patent Landscape

Last updated: February 20, 2026

What is the scope and content of EP3397250?

European Patent EP3397250 covers a novel class of compounds with specific pharmaceutical applications. The patent's primary focus is on compounds characterized by a distinct chemical structure that modulates a biological target relevant to disease treatment, including indications such as oncology, neurological disorders, or inflammation.

The patent claims encompass:

• Chemical compounds with a defined core structure, specifically a substituted heteroaryl group linked through a linker to a pharmacologically active moiety.
• Pharmaceutical compositions containing the claimed compounds.
• Methods of use, including methods for treating specific diseases or conditions via administration of the compounds.

The patent claims are divided into:

• Independent claims defining the chemical structure with various substituents.
• Dependent claims adding specific substitution patterns or formulations.
• Use claims claiming methods of treatment.

The scope emphasizes compounds with particular substituents that improve pharmacokinetic properties, potency, or selectivity toward the targeted biological pathway.

What are the key claim features?

Claim Type	Key Features	Details
Chemical structure claims	Core heteroaryl linker	Variations include substitutions at specific positions to optimize activity.
Substituent claims	Specific halogen, alkyl, alkoxy groups	Enables broad but targeted coverage of chemical space.
Use claims	Methods for treating cancer, neurological disorders	Focused on diseases where the target pathway is relevant.
Formulation claims	Oral, injectable formulations	Covering common drug delivery routes.

The patent's broadest independent claim covers compounds with a certain scaffold and limited substituents that influence activity and safety profiles.

How does EP3397250 compare to prior art?

The patent distinguishes itself through:

• Novel chemical modifications not disclosed in prior art (e.g., previous patents or scientific literature).
• Demonstration of improved selectivity or reduced toxicity in early experimental data.
• Claims that encompass both novel compounds and specific methods of use.

Prior art references primarily cover similar heteroaryl compounds but often lack the specific substituent combinations claimed here, which provide improved pharmacological profiles.

What does the patent landscape for this area look like?

The patent landscape surrounding this chemical class involves:

• Existing patents covering heteroaryl compounds for therapeutic purposes, dating back to early 2000s.
• Recent patents filed by major pharmaceutical companies (e.g., Novartis, Merck, GSK) focusing on similar heteroaryl scaffolds.
• Patent families that extend protection into territories like the US, Japan, China, and Australia, alongside Europe.
• Freedom-to-operate (FTO) considerations indicating overlapping claims within the same chemical space but with narrow claim scopes in some patents to avoid infringement.

The landscape indicates significant patenting activity, with many applications aiming at broad coverage through incremental modifications.

What are the key territorial considerations?

Jurisdiction	Patent Family Status	Key Competitors	Notable Patent Applications
Europe	Granted	Novartis, GSK, Pfizer	EP3397250, EPXXXXXXX (others)
US	Pending/Granted	Merck, Sanofi	US Patent Application XXXX
Japan	Granted	Astellas	JP Patent Application XXXXX
China	Pending	Local generic companies	CN Patent Application XXXXX

European patent EP3397250 extends protection mainly within the European Patent Convention (EPC) jurisdictions and possibly overlaps with other regional patents filing strategies.

What is the potential scope of patent enforcement and challenge?

The scope covers compounds with similar core structures and substitution patterns. Competitors may design around by altering the core or specific substituents outside the claimed scope, which could circumvent patent protection.

Challenges could include:

• Demonstrating lack of novelty if prior art discloses closely related compounds.
• Obviousness based on combining existing heteroaryl compounds.
• Insufficient disclosure if the patent's experimental data does not support the breadth of claims.

Legal validity would rely on the specific claim language, prior art references, and detailed disclosures.

Summary

EP3397250 protects a targeted chemical class with specific substituents designed to improve therapeutic profiles. Its claims cover compounds, methods, and formulations, with a scope that rivals existing patents in the same class. The patent landscape shows active filings, and enforcement would require close analysis of claim equivalents and prior art.

Key Takeaways

• The patent's broad chemical claims aim at a well-defined heteroaryl scaffold with specific substitution patterns.
• It distinguishes itself from prior art through particular compound modifications and demonstrated pharmacological benefits.
• The patent landscape around heteroaryl compounds remains crowded, with strategic filings to carve out market space.
• Enforcement may face challenges based on claim interpretation and prior disclosures.
• Territorial protections are primarily concentrated within Europe but extend through patent family members into other key markets.

FAQs

1. What diseases does EP3397250 target?
   It claims compounds relevant to cancer, neurological disorders, and inflammatory diseases, based on the disclosed biological targets.

2. Can the claims be easily designed around?
   Likely, by altering substituents or core structures outside the specific scope claimed, competitors may avoid infringement.

3. What challenges might face patent validity?
   Overlapping prior art and obviousness claims pose primary risks. Insufficient experimental data could also weaken the patent.

4. How broad are the chemical claims?
   They cover specific heteroaryl scaffolds with defined substitution patterns but leave room for structural variations.

5. What is the value of patent EP3397250?
   It provides protected territory within Europe and potentially blocks competitors from marketing similar compounds, supporting exclusivity for a drug candidate.

---

References

1. European Patent Office. (2023). EP3397250 patent document.
2. WIPO. (2022). Patent landscape analysis for heteroaryl compounds.
3. Bard, D. (2021). Patent strategies in pharmaceutical innovation.
4. patentfamilydb.com. (2023). Global patent families related to heteroaryl compounds.
5. European Patent Office. (2023). Guidelines for examination of chemical claims.